Some of them are expected to become part of our practice routine and change our therapeutic paradigms in the near future: circulating tumor DNA (ctDNA), POLE alteration, KRASG12C mutation, FGFR fusions, altered DNA damage repair (DDR) genes, tumor mutational burden (TMB) and consensus molecular subtypes classification (CMS), as well as ALK/RET/ROS fusions [30]. This evidence concerns the gene RET and neoplasm.